AU2009218456A1 - Combination comprising a cannabinoid receptor binding compound and an opioid - Google Patents

Combination comprising a cannabinoid receptor binding compound and an opioid Download PDF

Info

Publication number
AU2009218456A1
AU2009218456A1 AU2009218456A AU2009218456A AU2009218456A1 AU 2009218456 A1 AU2009218456 A1 AU 2009218456A1 AU 2009218456 A AU2009218456 A AU 2009218456A AU 2009218456 A AU2009218456 A AU 2009218456A AU 2009218456 A1 AU2009218456 A1 AU 2009218456A1
Authority
AU
Australia
Prior art keywords
pain
combination
alkyl
receptor binding
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009218456A
Other languages
English (en)
Inventor
Thomas George Evans
Donald Johns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2009218456A1 publication Critical patent/AU2009218456A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2009218456A 2008-02-28 2009-02-26 Combination comprising a cannabinoid receptor binding compound and an opioid Abandoned AU2009218456A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08152104.9 2008-02-28
EP08152104 2008-02-28
PCT/EP2009/052297 WO2009106574A2 (en) 2008-02-28 2009-02-26 Combinations for treating hiv-associated pain

Publications (1)

Publication Number Publication Date
AU2009218456A1 true AU2009218456A1 (en) 2009-09-03

Family

ID=39415383

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009218456A Abandoned AU2009218456A1 (en) 2008-02-28 2009-02-26 Combination comprising a cannabinoid receptor binding compound and an opioid

Country Status (11)

Country Link
US (1) US20090281194A1 (enExample)
EP (1) EP2257281A2 (enExample)
JP (1) JP2011513278A (enExample)
KR (1) KR20100126441A (enExample)
CN (1) CN101945650A (enExample)
AU (1) AU2009218456A1 (enExample)
BR (1) BRPI0907805A2 (enExample)
CA (1) CA2716405A1 (enExample)
EA (1) EA201001363A1 (enExample)
MX (1) MX2010009507A (enExample)
WO (1) WO2009106574A2 (enExample)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
GB0012795D0 (en) * 2000-05-25 2000-07-19 Novartis Ag Organic compounds
GB0028702D0 (en) * 2000-11-24 2001-01-10 Novartis Ag Organic compounds
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
GB0504950D0 (en) * 2005-03-10 2005-04-20 Novartis Ag Organic compositions
WO2007006732A1 (en) * 2005-07-11 2007-01-18 N.V. Organon Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist)

Also Published As

Publication number Publication date
BRPI0907805A2 (pt) 2015-07-14
JP2011513278A (ja) 2011-04-28
US20090281194A1 (en) 2009-11-12
WO2009106574A3 (en) 2009-12-17
CA2716405A1 (en) 2009-09-03
EA201001363A1 (ru) 2011-04-29
EP2257281A2 (en) 2010-12-08
KR20100126441A (ko) 2010-12-01
CN101945650A (zh) 2011-01-12
WO2009106574A2 (en) 2009-09-03
MX2010009507A (es) 2010-09-24

Similar Documents

Publication Publication Date Title
US11446309B2 (en) Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
RU2508110C2 (ru) КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek
JP5751831B2 (ja) 鎮痛耐性抑制剤
JP2015512425A (ja) チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
KR102517650B1 (ko) 유방암의 치료를 위한 조합물 요법
US20240342156A1 (en) Methods for treating pain
KR20220113411A (ko) KV7 칼륨 채널 개방제(opener)의 통증 치료를 위한 용도
CA2892578C (en) Pharmaceutical combinations of a pck inhibitor and a mek inhibitor for use in treatment of cancer
JP2018515547A (ja) オピオイドとｎ−アシルエタノールアミンの組み合わせ
AU2009218456A1 (en) Combination comprising a cannabinoid receptor binding compound and an opioid
AU2004233582B2 (en) Pharmaceutical compositon comprising a cathepsin S inhibitor and an opioid
EP1797883A2 (en) Pharmaceutical composition comprising a cathepsin S inhibitor and an opioid
EA015503B1 (ru) Применение 4-циклопропилметокси-n-(3,5-дихлор-1-оксидопиридин-4-ил)-5-(метокси)пиридин-2-карбоксамида для лечения черепно-мозговых травм
EP1465633A1 (en) Quinazolinone compounds in combined modalities for improved cancer treatment
Rinnier et al. Overview and antagonists of NMDA receptors
JP2009510158A (ja) 毒物依存症の治療におけるネボグラミンの使用
CN101835474A (zh) 用于在狗中治疗淋巴瘤的伊达比星
NZ786609A (en) Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
WO2005039593A1 (en) Combinations comprising ampa receptor antagonists for the treatment of neuropathic pain

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application